Ubac
Streptococcus uberis vaccine (inactivated)
Table of contents
Overview
An overview of Ubac and why it is authorised in the EU
Ubac is a vaccine used in cows and heifers (female cattle that have not yet calved) to reduce clinical mastitis (udder infections with visible signs in milk or the udder) caused by bacteria called Streptococcus uberis, which can reduce milk production. Ubac is also used to reduce the somatic cell count (SCC) in milk, which is a measure of mastitis without visible signs (subclinical mastitis). Ubac contains the active substance called biofilm adhesion component including lipoteichoic acid, which is derived from the sticky film produced by Streptococcus uberis strain 5616.
Authorisation details
Product details | |
---|---|
Name |
Ubac
|
Agency product number |
EMEA/V/C/004595
|
Active substance |
Lipoteichoic acid from Biofilm Adhesion Component of Streptococcus uberis, strain 5616
|
International non-proprietary name (INN) or common name |
Streptococcus uberis vaccine (inactivated)
|
Species |
Cattle
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI02AB
|
Publication details | |
---|---|
Marketing-authorisation holder |
Laboratorios Hipra, S.A.
|
Revision |
1
|
Date of issue of marketing authorisation valid throughout the European Union |
26/07/2018
|
Contact address |
Avda. La Selva,
135 Amer 17170 Girona Spain |
Product information
03/12/2021 Ubac - EMEA/V/C/004595 - IB/0006
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by Streptococcus uberis, to reduce the somatic cell count in Streptococcus uberis positive quarter milk samples and to reduce milk production losses caused by Streptococcus uberis intramammary infections.